DIFFERENCES OF 25-HYDROXYVITAMIN D SERUM LEVEL BETWEEN LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA PATIENTS IN HAJI ADAM MALIK GENERAL HOSPITAL MEDAN

Handoko Halim, Ratna Akbari Ganie, Gontar Alamsyah Siregar

Abstract


Liver cirrhosis is the third largest cause of death after cardiovascular and cancer. HCC is a liver malignancy that
requires early diagnosis. Biological effects of vitamin D include the effects of anti-proliferation, anti-angiogenesis,
pro-differentiation, anti-in􀃸ammatory, pro-apoptosis, and immunity regulation. Previous studies reported that chronic liver patients had
low levels of 25-hydroxyvitamin D. The aim of this study is to differ 25-hydroxyvitamin D serum level between liver cirrhosis and
hepatocellular carcinoma patients. Cross-sectional study of 32 consecutive admitted patients in Haji Adam Malik General Hospital Medan
from December 2017 to March 2018. Patients were classi􀃶ed as liver cirrhosis and hepatocellular carcinoma patients. Full blood count,
hemostasis and liver function test were done. AFP and 25-hydroxyvitamin were measured. Univariate analysis and bivariate were done with
SPSS version 24. There was no signi􀃶cant difference between 25-hydroxyvitamin D serum level on liver cirrhosis and hepatocellular
carcinoma patients (p = 0.052).


Keywords


liver cirrhosis, hepatocellular carcinoma, AFP, 25-hydroxyvitamin D

Full Text:

PDF

References


WHO. Age-standardized death rates, liver cirrhosis (15+). 2012. Global Health Observatory data repository.

Nurdjanah, S. SirosisHati. Dalam : S Setiati, et al. Buku Ajar IlmuPenyakitDalam. ed. 6. Jakarta :InternaPublishing, 2014:1978-83.

Stiphany, Hiswani and Jemadi. KarakteristikPenderitaSirosisHatiRawatInap di RSUD dr. Pirngadi Medan Tahun 2010-2011. portalgaruda. http://download.portalgaruda.org/article.php?article=51529&val=4108

McGlynn, KA, Petrick, JL and WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223-38.

Ferlay, J, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr, accessed on 12/December/2016.

Rasyid, A. TemuanUltrasonografiKankerHatiHepatoSelular (Hepatoma). 2, Medan. MajalahKedokteran Nusantara. 2006;39:104-8.

Youssef, E.M.I., Ali, H.A.A., Ewieda, G.H., et al. 25-Hydroxy Vitamin D: Novel Biomarker for the Diagnosis of Hepatocellular Carcinoma. Research In Cancer and Tumor. 2014;3(1): 19 -25.

Hammad, LN, et al. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis? J Immunotoxicol. 2013:Early online;1-7.

Trepo, E, et al. Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. J Hepatol. 2013:59;344-50.

Lange, CM, et al. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS ONE. 2013;8(5):e64053.

Gopal P, Yopp CC, Waljee AK, Chiang J, Nehra M, Kandunoori P and Singal AG. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. ClinGastroenterolHepatol. 2014;12(5):870-7.

Sameea EA, Zakareya T, Metwaly K, YoussefAAR, Kamal HM, and Abdalla WM. Serum soluble CD25 in hepatocellular carcinoma, shall we BE able to change the natural history? International Journal of Medicine and Medical Research. 2017;3(2):10-5.

Khoury T, Ayman AR, Cohen J, Daher S, Shmuel C and Mizrahi M. The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going . Digestion. 2016;93:149–59.

Zahra MK, Attia TE, Ahmad AY and Othman MA. Serum Galectin-3 Levels in Patients with Hepatocellular Carcinoma, Liver Cirrhosis and Chronic Viral Hepatitis. The Egyptian Journal of Hospital Medicine. 2018;70(1):132-9.

Li B, Li B, Guo T, Sun Z, Li X, Li X, et al. The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma. BioMed Research International. 2017; 5358615.

Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B, et al. Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients. PLos One. 2012;7(10):e47687.

Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Mori S, et al. Aspartate aminotransferase-to-platelet ratio index is associated with liver cirrhosis in patients undergoing surgery for hepatocellular carcinoma. J Surg Res. 2015;14(1):63-8.

Nishikawa H, Kita R, Kimura T, Endo M, Ohara Y, Sakamoto A, et al. Proposal of the performance status combined Japan Integrated Staging system in hepatocellular carcinoma complicated with cirrhosis. International Journal Of Oncology. 2015;46:2371-9.

Xie W, Cao Y, Xu M, Wang J, Zhou C, Yang X, et al. Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. Scientific Reports. 2017;7:10289.

Dong ZR, Zou J, Sun D, Shi GM, Ke AW, Cai JB, et al. Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. J Cancer. 2017;8(18):3862-7.

Mohammed MA, Omar NM, Mohammed SA and Deiab AG. The Significance of Vitamin D Receptor Gene Polymorphisms for Susceptibility to Hepatocellular Carcinoma in Subjects Infected with Hepatitis C Virus. GastroenterolHepatol Open Access. 2017;7(4):00246.

Mohammed, H.A.A., Yang, J.D., Giama, N.H., et al. 2017. Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. Liver Cancer. 2017;6:126-36.

Bellissimo F, Pinzone MR, Cacopardo B and Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21(42):12003-21.

Fateen W and Ryder SD. Screening for hepatocellular carcinoma: patient selection and perspectives. Journal of Hepatocellular Carcinoma. 2017;4:71–9.

McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for Hepatocellular Carcinoma in Alaska Natives Infected With Chronic Hepatitis B: A 16-Year Population-Based Study. Hepatology. 2000;32:842-46.

Lou J, Zhang L, Lv S, Zhang C and Jiang S. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9.

Pincus, MR and Abraham, NZ. Interpreting Laboratory Results. Dalam: RA McPherson and MR Pincus. Henry's Clinical Diagnosis and Management By Laboratory Methods. St. Louis : Elsevier, 2017;23:84-101.

Anty R, Tonohouan M, Ferrari-Panaia P, Piche T, Pariente A, Anstee QM et al. Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. ClinTranslGastroenterol. 2014;5(5):e56.

Chen EQ, Shi Y and Tang H. New insight of vitamin D in chronic liver diseases. HepatobiliaryPancreat Dis Int. 2014;13(6):580-5.

Stokes CS, Krawczyk M, Reichel C, Lammert F and Grunhage F. Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. Eur J Clin Invest. 2014;44(2):176–83.

Konstantakis, C., Tselekouni, P., Kalafateli, M., et al. Vitamin D deficiency in patients with liver cirrhosis. Annals of Gastroenterology. 2016;29:297-306.

Paternostro R, Wagner D, Reiberger T. Low 25-OH-vitaminD levels reflect hepatic dysfunction andare associated with mortality in patientswith liver cirrhosis. Wien Klin Wochenschr.2017;129:8–15.

Borges PS, Guimaraes VM, Farias JLR, et al.Absence of Relationship between Serum Vitamin D Levels with Chronic Hepatitis C. J GastroenterolHepatol Res. 2016;5(2).

Finkelmeier, F, et al. Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma – a prospective cohort study. Aliment PharmacolTher. 2014;39:1204-12.

Finkelmeier F, Bettinger D, Koberle V, Schultheiß M, Zeuzem S, Kronenberger B, et al. Single measurement of hemoglobin predicts outcome of HCC patients. Med Oncol. 2014;31:806.

Hammad, LN, et al. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis? J Immunotoxicol. 2013:Early online;1-7.

Fedirko V, Duarte-Salles T, Bamia C, et al. Prediagnostic Circulating Vitamin D Levels and Risk of Hepatocellular Carcinoma in European Populations: A Nested Case-Control Study. Hepatology.2014;60:1222-30.


Refbacks

  • There are currently no refbacks.